Research Dynamics
Report on Relief Therapeutics by Research Dynamics: Company update on collaborations
EQS Group-News: Research Dynamics / Key word(s): Research Update This report is published by Research Dynamics, an independent research boutique Under the terms of the agreement, PX’Therapeutics will optimize the existing production process for recombinant IL-6, a 185-amino acids cytokine, in Chinese hamster ovary (CHO) cells. PX’Therapeutics will also produce the clinical material that will be used for clinical trials. We believe that the expertise of PX’Therapeutics in developing recombinant proteins will benefit Relief in efficiently conducting its clinical trials for atexakin alfa. Further, PX’Therapeutics may develop a commercial-scale process for the production of the drug.
Under the terms of the agreement, FirstString will seek US government financial support, develop relevant collaborations, and provide resources towards the Food and Drug Administration (FDA) requirements on the constitution of an Investigational New Drug (IND) application dossier for atexakin alfa in diabetic neuropathy. This collaboration will also enable Relief to get better access to US-based grant funding from US governmental sources such as the National Institutes of Health (NIH). Given FirstString’s solid track record in obtaining grant-based funding, we believe Relief will be greatly benefitted in raising the necessary funds to conduct the clinical trials for atexakin alfa. This collaboration agreement may also pave the way for atexakin alfa to be tested in US clinical trials.
Our current approach values the company at CHF0.19 per share, with upside potential. We believe that Relief might enter into similar partnerships / agreements in the future. It may also look towards other attractive acquisition opportunities (other than FirstString) which would consolidate its pipeline of drug candidates. Additional features: Document: http://n.eqs.com/c/fncls.ssp?u=UAQQFVIBET Document title: Relief_News update_Research Dynamics_26.10.2016
End of Corporate News |